About Amalgam Rx
Amalgam Rx is a private company based in Wilmington, Delaware. It has reported $27,340,416 raised in five offerings on Form D since March 2016. Its chief executive is Ryan Sysko.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 8, 2025 | Aug 15, 2025 | $7,886,530fully sold | 28 | $281K | Equity, DebtRule 506(b) | Form D ↗ |
| Dec 16, 2022 | Jan 3, 2023 | $17,365,000of $45.0M target | 62 | $280K | EquityRule 506(b) | Form D ↗ |
| Sep 23, 2019 | Oct 8, 2019 | $650,000of $750K target | 5 | $130K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 16, 2017 | Jun 30, 2017amended May 3, 2019 | $1,223,886of $2.0M target | 27 | $45,329 | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Mar 14, 2016 | Mar 24, 2016 | $215,000of $500K target | 7 | $30,714 | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $27,340,416 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Amalgam Rx's Form D filed Aug 15, 2025.
Earlier filings also listed Sarwar Islam (director, last listed Oct 2019).